SEC opens informal probe of Elan's Tysabri withdrawal

04/12/2005 | Wall Street Journal, The

Dublin-based Elan reported the U.S. SEC is conducting an informal inquiry regarding the Feb. 28 announcement that Elan and Biogen Idec were withdrawing the multiple sclerosis drug Tysabri from the market. Elan's stock price dropped following the announcement, and a company spokeswoman said the SEC "typically conducts a routine information gathering" when there is a significant change in stock prices.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Claims Director
PacificSource
Springfield, OR
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA